Vilicom Selects Mavenir to Deliver UK’s First Off-Shore Open RAN based vRAN Private Network for Windfarm Connectivity
26.8.2021 10:00:00 EEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announces today that UK based wireless telecommunications provider, Vilicom is using the MAVair solution as a critical component in delivering UK’s first off-shore private LTE network for windfarm communications and connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005014/en/
Moray East Offshore Windfarm, Scotland, United Kingdom. Vilicom Selects Mavenir to Deliver UK’s First Off-Shore Open RAN based vRAN Private Network for Windfarm Connectivity. (Photo: Business Wire)
The MAVair family includes the flexible Open Virtualised RAN (Open vRAN) where the evolved RAN architecture, designed with cloud-native virtualisation techniques, enables the RAN to flex and adapt based on usage and coverage. Mavenir’s Open vRAN platform enables Vilicom to provide reliable, scalable, high throughput solution meeting low latency requirement in a challenging environment. The software application runs on commoditised hardware providing cost effectiveness, high flexibility and agility to network operators, whilst providing one architecture for many different user scenarios.
The Vilicom network provides advanced communications and connectivity to sea vessels and workers operating inside the boundaries of the windfarm off the coast of Scotland. The connectivity also allows workers to be in touch on a regular basis through video calls and emails whilst they are at sea.
The Moray East offshore windfarm project is aimed at generating electricity using renewable energy; it will be able to fulfil approximately 40% of the total electricity demand in Scotland and can power-up to 950,000 homes in the UK.
“Building efficiencies into the construction and operations of a windfarm is a challenge without superfast and reliable connectivity. Vilicom will provide network connectivity to all project operating sea vessels and provides functionality that enables communication not only between workers at sea but also communication back home and for use in leisure time,” states Sean Keating, CEO of Vilicom.
“Mavenir is delighted to partner with Vilicom for this important and equally complex private network system. Private networks are increasingly becoming more prevalent and we look forward to collaborating with Vilicom to develop further such use cases and applications. This project highlights the relevance and importance of advanced communications in a real application scenario,” states Stefano Cantarelli, Chief Marketing Officer of Mavenir.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Vilicom:
Vilicom is at the forefront of designing, installing and managing the global networks that give people in over 20 countries and four continents the freedom to communicate and work from anywhere. Vilicom’s consultancy and system integration services harness wireless technology, data and intelligent analytics across every industry sector to deliver unprecedented productivity and efficiencies. Vilicom works with some of the biggest (and, indeed, the smallest) technology-driven companies in the world, offering insight-led consultancy and advice on everything from vendor selections and technology strategy to mergers, acquisitions and project delivery.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005014/en/
Contact information
Mavenir PR Contacts:
Mavenir
Emmanuela Spiteri
PR@mavenir.com
Global PR (EMEA)
Kevin Taylor
KTaylor@GlobalResultsPR.com
Global PR (US)
Casey Bush
mavenir@GlobalResultsPR.com
Vilicom PR Contacts:
PR Consultant
Leila Hrycyszyn
leila@leilapr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom